Abstract:During the past quarter century, the diagnosis and treatment of cystic fibrosis (CF) have been transformed by molecular sciences that initiated a new era with discovery of the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene. The knowledge gained from that breakthrough has had dramatic clinical impact. Although once a diagnostic dilemma with long delays, preventable deaths, and irreversible pathology, CF can now be routinely diagnosed shortly after birth through newborn screening programs. This strategy of pre-symptomatic identification has eliminated the common diagnostic "odyssey" that was a failure of the healthcare delivery system causing psychologically traumatic experiences for parents. Therapeutic advances of many kinds have culminated in CFTR modulator treatment that can reduce the effects of or even correct the molecular defect in the chloride channel —the basic cause of CF. This astonishing advance has transformed CF care as described fully herein. Despite this impressive progress, there are challenges and controversies in the delivery of care. Issues include how best to achieve high sensitivity newborn screening with acceptable specificity; what course of action is appropriate for children who are identified through the unavoidable incidental findings of screening tests (CFSPID/CRMS cases and heterozygote carriers); how best to ensure genetic counseling; when to initiate the very expensive but life-saving CFTR modulator drugs; how to identify new CFTR modulator drugs for patients with non-responsive CFTR variants; how to adjust other therapeutic modalities; and how to best partner with primary care clinicians. Progress always brings new challenges, and this has been evident worldwide for CF. Consequently, this article summarizes the major advances of recent years along with controversies and describes their implications with an international perspective.

The ageing of people living with cystic fibrosis: what to expect now?

What the future holds: cystic fibrosis and aging

The ageing of Cystic Fibrosis patients with new modulators: current gaps and challenges

New drugs, new challenges in cystic fibrosis care

Exploring the complexity of cystic fibrosis (CF) and psychosocial wellbeing in the 2020s: Current and future challenges

Advances in the restoration of CFTR in children and pwCF with "mild disease"

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy

Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians

Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes

Cystic fibrosis in the year 2020: A disease with a new face

FGF receptors mediate cellular senescence in the cystic fibrosis airway epithelium

Improving gastrointestinal health in children and young people with cystic fibrosis

Toward a Broader Understanding of Cystic Fibrosis Epidemiology and Its Impact on Clinical Manifestations

Current characteristics, challenges and coping strategies of young people with cystic fibrosis as they transition to adulthood

Ageing and ivacaftor: unravelling the long-term effects

The future of cystic fibrosis: A global perspective

Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series

Prognosis-Based Early Intervention Strategies to Resolve Exacerbation and Progressive Lung Function Decline in Cystic Fibrosis

[Therapeutics in cystic fibrosis: Clinical revolution and new challenges]

Education, employment, and income among people living with cystic fibrosis across three decades – A matched cohort study using Danish health registries

Evolving data on risk and current screening recommendations for colorectal cancer in cystic fibrosis: Pre- and posttransplant